Nothing Special   »   [go: up one dir, main page]

NO20035605D0 - Pediatrisk formulering av gatifloxacin - Google Patents

Pediatrisk formulering av gatifloxacin

Info

Publication number
NO20035605D0
NO20035605D0 NO20035605A NO20035605A NO20035605D0 NO 20035605 D0 NO20035605 D0 NO 20035605D0 NO 20035605 A NO20035605 A NO 20035605A NO 20035605 A NO20035605 A NO 20035605A NO 20035605 D0 NO20035605 D0 NO 20035605D0
Authority
NO
Norway
Prior art keywords
gatifloxacin
pediatric formulation
pediatric
formulation
Prior art date
Application number
NO20035605A
Other languages
English (en)
Inventor
Krishnaswamy Srinivas Raghavan
Sunanda A Ranadive
Kenneth S Bernbeneck
Loutfy Benkerrour
Veronique Trognon
Richard G Corrao
Luigi Esposito
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20035605D0 publication Critical patent/NO20035605D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Seasonings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20035605A 2001-06-20 2003-12-16 Pediatrisk formulering av gatifloxacin NO20035605D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29962501P 2001-06-20 2001-06-20
PCT/US2002/014596 WO2003000175A2 (en) 2001-06-20 2002-05-10 Pediatric formulation of gatifloxacin

Publications (1)

Publication Number Publication Date
NO20035605D0 true NO20035605D0 (no) 2003-12-16

Family

ID=23155586

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035605A NO20035605D0 (no) 2001-06-20 2003-12-16 Pediatrisk formulering av gatifloxacin

Country Status (29)

Country Link
US (1) US6589955B2 (no)
EP (1) EP1406572A4 (no)
JP (1) JP4617475B2 (no)
KR (1) KR100888519B1 (no)
CN (1) CN1264514C (no)
AR (1) AR034483A1 (no)
AU (1) AU2002345534B2 (no)
BG (1) BG108444A (no)
BR (1) BR0209692A (no)
CA (1) CA2450742A1 (no)
CZ (1) CZ20033487A3 (no)
EE (1) EE200400018A (no)
GE (1) GEP20053610B (no)
HR (1) HRP20031027A2 (no)
HU (1) HUP0401497A2 (no)
IL (1) IL158863A0 (no)
IS (1) IS7048A (no)
MX (1) MXPA03011451A (no)
NO (1) NO20035605D0 (no)
NZ (1) NZ529611A (no)
PE (1) PE20030126A1 (no)
PL (1) PL366559A1 (no)
RU (1) RU2288218C2 (no)
SK (1) SK14152003A3 (no)
TW (1) TWI224004B (no)
UA (1) UA75656C2 (no)
WO (1) WO2003000175A2 (no)
YU (1) YU100303A (no)
ZA (1) ZA200309173B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1758557B1 (en) 2004-05-11 2011-07-13 Egalet Ltd. Swellable dosage form comprising gellan gum
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) * 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070051418A1 (en) * 2005-09-02 2007-03-08 Rowles Brian A Multilayer tubes
TW201010708A (en) * 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid
SI2346509T1 (sl) 2008-10-07 2020-08-31 Horizon Orphan Llc Inhalacija levofloksacina za zmanjšanje vnetja pljuč
NZ719761A (en) * 2008-10-07 2017-11-24 Raptor Pharmaceuticals Inc Aerosol fluoroquinolone formulations for improved pharmacokinetics
EP3569235A1 (en) 2009-09-04 2019-11-20 Horizon Orphan LLC Use of aerosolized levofloxacin for treating cystic fibrosis
CN102397552B (zh) * 2010-09-10 2016-06-08 广州自远生物科技有限公司 一种含喹诺酮类的药物复合制剂及其制备方法和应用
CN102397546A (zh) * 2010-09-10 2012-04-04 广州自远生物科技有限公司 一种用于嗅觉或味觉敏感型动物的药物给药方法
MX2015011760A (es) 2013-03-15 2016-06-10 Melinta Therapeutics Inc Metodos para tratar infecciones en pacientes obesos y con sobrepeso usando antibioticos.
US20180118747A1 (en) * 2017-01-03 2018-05-03 Thermolife International, Llc Method of isolating theacrine and composition comprising theacrine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO88836A2 (ro) 1983-10-11 1986-03-31 Institutul Pentru Controlul De Stat Al Medicamentului Si Cercetari Farmaceutice,Ro Procedeu de obtinere a comprimatelor cu eritromicina propionat de uz pediatric
JPH089597B2 (ja) 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
NL193682C (nl) 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US5405617A (en) 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
IT1255792B (it) 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US5407921A (en) 1993-07-01 1995-04-18 Kao Corporation Method for suppressing bitter taste
JP3449658B2 (ja) 1994-12-21 2003-09-22 杏林製薬株式会社 安定性に優れた8−アルコキシキノロンカルボン酸水和物並びにその製造方法
DE19633480A1 (de) 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
CA2227314A1 (en) * 1997-01-24 1998-07-24 Hoechst Aktiengesellschaft Preparation of concealed taste preparations of antibacterially active quinolone derivatives
GB9702799D0 (en) 1997-02-12 1997-04-02 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
DE19820801A1 (de) * 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
BR0012439A (pt) 1999-07-14 2002-04-02 Schering Plough Ltd Mascarando o sabor de preparações orais lìquidas de quinolona com a utilização de resinas de troca de ìon

Also Published As

Publication number Publication date
RU2288218C2 (ru) 2006-11-27
JP2005500306A (ja) 2005-01-06
JP4617475B2 (ja) 2011-01-26
HRP20031027A2 (en) 2005-10-31
MXPA03011451A (es) 2004-04-05
US6589955B2 (en) 2003-07-08
BG108444A (en) 2004-08-31
BR0209692A (pt) 2004-04-20
US20030028025A1 (en) 2003-02-06
UA75656C2 (en) 2006-05-15
CN1518449A (zh) 2004-08-04
YU100303A (sh) 2006-08-17
AR034483A1 (es) 2004-02-25
PL366559A1 (en) 2005-02-07
RU2003136068A (ru) 2005-02-10
NZ529611A (en) 2006-02-24
KR20040011543A (ko) 2004-02-05
EE200400018A (et) 2004-04-15
ZA200309173B (en) 2005-02-25
IS7048A (is) 2003-11-20
EP1406572A4 (en) 2005-05-25
WO2003000175A3 (en) 2003-04-10
CA2450742A1 (en) 2003-01-03
AU2002345534B2 (en) 2007-07-12
EP1406572A2 (en) 2004-04-14
TWI224004B (en) 2004-11-21
HUP0401497A2 (hu) 2004-12-28
CN1264514C (zh) 2006-07-19
PE20030126A1 (es) 2003-02-08
GEP20053610B (en) 2005-09-12
WO2003000175A2 (en) 2003-01-03
CZ20033487A3 (cs) 2004-05-12
IL158863A0 (en) 2004-05-12
KR100888519B1 (ko) 2009-03-11
SK14152003A3 (sk) 2004-06-08

Similar Documents

Publication Publication Date Title
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
NO20042121D0 (no) Kinolinforbindelse
ATE537831T1 (de) Orale aripiprazol-lösung
NO20033384L (no) Farmasoytisk formulering
DK1406628T3 (da) Tetrahydroquinolin-derivater
NO20043110L (no) Direkte komprimerbare formuleringer av azitromycin
DK1414409T3 (da) Stabiliseret oral suspensionsformulering
NO20033785L (no) Farmasöytisk formulering
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
NO20044916L (no) Preparater av sulfinylacetamid
FI20010558A (fi) Kappaleiden paikannus
NO20035605D0 (no) Pediatrisk formulering av gatifloxacin
NO20041968L (no) Anvendelse av cystationin
NO20021860L (no) Formulering av substituerte benzimidazoler
NO20042640L (no) Fremgangsmate for fremstilling av ekinocandinderivater
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
NO20035538D0 (no) Fremgangsmåte for fremstilling av zaleplon
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
NO20021730L (no) Ny formulering av mirtazapin
NO20023785L (no) Vanndispergerbar formulering av paroxetin
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
PT1392670E (pt) Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina
NO20034972L (no) Behandling av ADHD
FI20010844A0 (fi) Uusi äidinmaidonkorvikekoostumus
NO20044424L (no) Fremgangsmate for fremstilling av sertindol